Pharmacological stimulation of GAL1R but not GAL2R attenuates kainic acid-induced neuronal cell death in the rat hippocampus. 2016

Kristin Webling, and Jessica L Groves-Chapman, and Johan Runesson, and Indrek Saar, and Andreas Lang, and Rannar Sillard, and Erik Jakovenko, and Barbara Kofler, and Philip V Holmes, and Ülo Langel
Department of Neurochemistry, Stockholm University, Svante Arrheniusv. 16B, SE-10691, Stockholm, Sweden. Electronic address: kristin.webling@neurochem.su.se.

The neuropeptide galanin is widely distributed in the central and peripheral nervous systems and part of a bigger family of bioactive peptides. Galanin exerts its biological activity through three G-protein coupled receptor subtypes, GAL1-3R. Throughout the last 20years, data has accumulated that galanin can have a neuroprotective effect presumably mediated through the activation of GAL1R and GAL2R. In order to test the pharmaceutical potential of galanin receptor subtype selective ligands to inhibit excitotoxic cell death, the GAL1R selective ligand M617 and the GAL2R selective ligand M1145 were compared to the novel GAL1/2R ligand M1154, in their ability to reduce the excitotoxic effects of intracerebroventricular injected kainate acid in rats. The peptide ligands were evaluated in vitro for their binding preference in a competitive (125)I-galanin receptor subtype binding assay, and G-protein signaling was evaluated using both classical signaling and a label-free real-time technique. Even though there was no significant difference in the time course or severity of the kainic acid induced epileptic behavior in vivo, administration of either M617 or M1154 before kainic acid administration significantly attenuated the neuronal cell death in the hippocampus. Our results indicate the potential therapeutic value of agonists selective for GAL1R in the prevention of neuronal cell death.

UI MeSH Term Description Entries
D007608 Kainic Acid (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose. Digenic Acid,Kainate,Acid, Digenic,Acid, Kainic
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008297 Male Males
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001920 Bradykinin A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter. Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg,Bradykinin Acetate, (9-D-Arg)-Isomer,Bradykinin Diacetate,Bradykinin Hydrochloride,Bradykinin Triacetate,Bradykinin, (1-D-Arg)-Isomer,Bradykinin, (2-D-Pro)-Isomer,Bradykinin, (2-D-Pro-3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (2-D-Pro-7-D-Pro)-Isomer,Bradykinin, (3-D-Pro)-Isomer,Bradykinin, (3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (5-D-Phe)-Isomer,Bradykinin, (5-D-Phe-8-D-Phe)-Isomer,Bradykinin, (6-D-Ser)-Isomer,Bradykinin, (7-D-Pro)-Isomer,Bradykinin, (8-D-Phe)-Isomer,Bradykinin, (9-D-Arg)-Isomer,Arg Pro Pro Gly Phe Ser Pro Phe Arg
D006624 Hippocampus A curved elevation of GRAY MATTER extending the entire length of the floor of the TEMPORAL HORN of the LATERAL VENTRICLE (see also TEMPORAL LOBE). The hippocampus proper, subiculum, and DENTATE GYRUS constitute the hippocampal formation. Sometimes authors include the ENTORHINAL CORTEX in the hippocampal formation. Ammon Horn,Cornu Ammonis,Hippocampal Formation,Subiculum,Ammon's Horn,Hippocampus Proper,Ammons Horn,Formation, Hippocampal,Formations, Hippocampal,Hippocampal Formations,Hippocampus Propers,Horn, Ammon,Horn, Ammon's,Proper, Hippocampus,Propers, Hippocampus,Subiculums
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic

Related Publications

Kristin Webling, and Jessica L Groves-Chapman, and Johan Runesson, and Indrek Saar, and Andreas Lang, and Rannar Sillard, and Erik Jakovenko, and Barbara Kofler, and Philip V Holmes, and Ülo Langel
August 2013, Progress in neuro-psychopharmacology & biological psychiatry,
Kristin Webling, and Jessica L Groves-Chapman, and Johan Runesson, and Indrek Saar, and Andreas Lang, and Rannar Sillard, and Erik Jakovenko, and Barbara Kofler, and Philip V Holmes, and Ülo Langel
July 2009, Brain research,
Kristin Webling, and Jessica L Groves-Chapman, and Johan Runesson, and Indrek Saar, and Andreas Lang, and Rannar Sillard, and Erik Jakovenko, and Barbara Kofler, and Philip V Holmes, and Ülo Langel
June 2013, Experimental neurobiology,
Kristin Webling, and Jessica L Groves-Chapman, and Johan Runesson, and Indrek Saar, and Andreas Lang, and Rannar Sillard, and Erik Jakovenko, and Barbara Kofler, and Philip V Holmes, and Ülo Langel
June 2010, The Journal of endocrinology,
Kristin Webling, and Jessica L Groves-Chapman, and Johan Runesson, and Indrek Saar, and Andreas Lang, and Rannar Sillard, and Erik Jakovenko, and Barbara Kofler, and Philip V Holmes, and Ülo Langel
November 2006, Journal of neuroscience research,
Kristin Webling, and Jessica L Groves-Chapman, and Johan Runesson, and Indrek Saar, and Andreas Lang, and Rannar Sillard, and Erik Jakovenko, and Barbara Kofler, and Philip V Holmes, and Ülo Langel
October 2016, Rejuvenation research,
Kristin Webling, and Jessica L Groves-Chapman, and Johan Runesson, and Indrek Saar, and Andreas Lang, and Rannar Sillard, and Erik Jakovenko, and Barbara Kofler, and Philip V Holmes, and Ülo Langel
September 2004, Brain research,
Kristin Webling, and Jessica L Groves-Chapman, and Johan Runesson, and Indrek Saar, and Andreas Lang, and Rannar Sillard, and Erik Jakovenko, and Barbara Kofler, and Philip V Holmes, and Ülo Langel
January 1988, Neuropeptides,
Kristin Webling, and Jessica L Groves-Chapman, and Johan Runesson, and Indrek Saar, and Andreas Lang, and Rannar Sillard, and Erik Jakovenko, and Barbara Kofler, and Philip V Holmes, and Ülo Langel
January 2015, Biological & pharmaceutical bulletin,
Kristin Webling, and Jessica L Groves-Chapman, and Johan Runesson, and Indrek Saar, and Andreas Lang, and Rannar Sillard, and Erik Jakovenko, and Barbara Kofler, and Philip V Holmes, and Ülo Langel
September 2021, Cells,
Copied contents to your clipboard!